These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4015329)

  • 1. The interpretation of plasma haloperidol concentrations.
    Kirch DG; Bigelow LB; Wyatt RJ
    Arch Gen Psychiatry; 1985 Aug; 42(8):838-40. PubMed ID: 4015329
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma haloperidol levels: clinical response and fancy mathematics.
    Van Putten T; Marder SR; Mintz J
    Arch Gen Psychiatry; 1985 Aug; 42(8):835-8. PubMed ID: 4015328
    [No Abstract]   [Full Text] [Related]  

  • 3. The relationship between plasma haloperidol concentrations and clinical results.
    Palao DJ; Araúxo A; Haro JM; Brunet M; Bernardo M
    Arch Gen Psychiatry; 1996 Dec; 53(12):1167-9. PubMed ID: 8956684
    [No Abstract]   [Full Text] [Related]  

  • 4. Plasma haloperidol levels and clinical response.
    Smith RC
    Arch Gen Psychiatry; 1987 Dec; 44(12):1110-2. PubMed ID: 3689100
    [No Abstract]   [Full Text] [Related]  

  • 5. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
    Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
    Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
    Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
    J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond the therapeutic window: a case presentation.
    Schulz SC; Butterfield L; Garicano M; Narasimhachari N; Friedel RO
    J Clin Psychiatry; 1984 May; 45(5):223-5. PubMed ID: 6725212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
    Hollister LE; Kim DY
    Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients.
    Lin KM; Poland RE; Nuccio I; Matsuda K; Hathuc N; Su TP; Fu P
    Am J Psychiatry; 1989 Oct; 146(10):1307-11. PubMed ID: 2782476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma drug level and clinical response.
    Cooper TB; Volavka J; Czobor P
    J Clin Psychopharmacol; 1992 Apr; 12(2):134-6. PubMed ID: 1573036
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response.
    Piscitelli SC; Frazier JA; McKenna K; Albus KE; Grothe DR; Gordon CT; Rapoport JL
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():94-7. PubMed ID: 7961584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
    Santos JL; Cabranes JA; Vazquez C; Fuentenebro F; Almoguera I; Ramos JA
    Biol Psychiatry; 1989 Aug; 26(4):381-8. PubMed ID: 2669981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
    Van Putten T; Marder SR; Mintz J; Poland RE
    Am J Psychiatry; 1992 Apr; 149(4):500-5. PubMed ID: 1554036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
    Magliozzi JR; Hollister LE; Arnold KV; Earle GM
    Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
    Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
    J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
    Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C
    Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haloperidol plasma levels and dose optimization.
    Coryell W; Miller DD; Perry PJ
    Am J Psychiatry; 1998 Jan; 155(1):48-53. PubMed ID: 9433338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
    Miller DD; Perry PJ; Kelly MW; Coryell WH; Arndt SV
    J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder.
    Volavka J; Cooper TB; Czobor P; Meisner M
    Psychopharmacol Bull; 1996; 32(1):75-9. PubMed ID: 8927679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
    Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
    Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.